Biomarkers and the Immune System: A New Era in Eczema and Skin Health Management

Biomarker testing is emerging as a transformative tool in understanding and supporting immune system function, with promising implications for chronic inflammatory skin conditions such as eczema and topical steroid withdrawal (TSW). By identifying molecular signatures of immune dysregulation, biomarkers can guide more personalized interventions and track the body’s response to treatment over time.

Understanding Biomarker Testing and Immunity

Biomarkers are measurable biological indicators—such as proteins, cytokines, or gene expression patterns—that reflect immune activity or dysfunction. In immunology, cytokines including interleukins (ILs), chemokines, and interferons play central roles in orchestrating immune responses and are increasingly used as biomarkers for disease monitoring and diagnosis. Studies in both infectious and inflammatory contexts have shown that blood-based biomarker analysis, such as cytokine profiling, provides valuable insights into how the immune system responds to stressors or pathogens, and can help identify immune imbalances that underlie chronic inflammation or autoimmune disease.​

Improving immune function is not about stimulating the system indiscriminately—it involves restoring balance. Chronic inflammation, allergic sensitization, and immune insufficiency can all stem from dysregulated communication among immune cells. Biomarker testing enables clinicians to pinpoint which pathways are overactive or suppressed, allowing for targeted strategies to rebalance immune activity.

Immune Biomarkers in Eczema and Skin Health

Atopic dermatitis (AD), commonly known as eczema, exemplifies a condition driven by immune system imbalance. It involves an overactivation of the Th2 (type 2 helper T cell) pathway, leading to increased production of cytokines such as interleukin-4 (IL-4), IL-13, and IL-31, which drive inflammation, itching, and barrier dysfunction. Recent studies highlight IL-13 as a key biomarker that not only reflects disease severity but can also predict response to biologic treatments like dupilumab, an IL-4/IL-13 inhibitor.​

Emerging biomarker-based diagnostics are helping to identify early indicators of eczema. A landmark Danish study demonstrated that non-invasively collected skin samples containing elevated levels of IL-8, IL-18, and thymus and activation-regulated chemokine (TARC/CCL17) can predict the development and severity of atopic eczema within the first two years of life. These immune-related biomarkers reveal subclinical immune activation well before visible skin symptoms appear—an insight that could lead to early intervention and prevention.​

In adults, biomarker mapping of gene expression in inflamed skin provides further insight into disease endotypes, or molecular subtypes. A 2024 study established a molecular “immune map” to classify inflammatory skin diseases such as psoriasis and eczema based on specific immune gene modules, improving the diagnostic accuracy of ambiguous skin conditions. This molecular profiling supports precision dermatology, where therapies are matched to a patient’s dominant immune signature.​

How Biomarker Testing Could Support Immune Resilience

By providing a window into the immune system’s function, biomarker testing can reveal micronutrient deficiencies, chronic inflammation, oxidative stress, and immune regulation issues that underpin eczema severity. For example, C-reactive protein (CRP) and pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) or IL-6 can signal systemic inflammation that may worsen skin barrier integrity.​

Addressing these imbalances through targeted nutrition, stress management, and microbiome-supporting interventions could help improve immune resilience. Biomarkers related to vitamin D, omega-3 fatty acid status, or gut-derived metabolites are also being explored for their links to skin immune regulation. Observing how these biomarkers shift over time offers a data-driven approach to evaluating the effectiveness of holistic or integrative therapies aimed at immune restoration.

Topical Steroid Withdrawal and Immune Dysregulation

Topical steroid withdrawal (TSW) represents a complex form of immune rebound and dysregulation that can occur when potent steroid creams used for eczema are suddenly discontinued. Research published by the NIH in the Journal of Investigative Dermatology highlights the biochemical roots of TSW, suggesting that chronic steroid use alters local and systemic immune responses, potentially affecting cortisol regulation and inflammatory pathways.​

The condition is characterized by intense redness, burning, swelling, and hypersensitivity of the skin—sometimes extending to areas not previously affected by eczema. Patients may also experience systemic symptoms such as fatigue, gland swelling, and disrupted thermoregulation. Although TSW is not officially classified as a distinct diagnosis, biomarkers could hold the key to distinguishing it from eczema flares and monitoring recovery.​

Early investigations have begun exploring immune markers associated with steroid-induced skin dysregulation. Patterns of altered cytokine expression and impaired skin barrier enzymes, such as reduced ceramide production and pH imbalance, have been linked to chronic steroid exposure. More recently, reports suggest that biomarker patterns in TSW overlap partially with those of severe eczema but may include distinct fingerprints related to immune suppression and adrenal axis disruption.​

Skin Diagnostic Advances and the Future of Care

Modern skin diagnostic tools increasingly incorporate biomarker analysis, combining genetic, proteomic, and transcriptomic profiling to reveal the underlying immune activity in the skin. Bioinformatics-based analyses have identified differentially expressed genes associated with immune cell infiltration in atopic dermatitis, providing opportunities for more personalized therapeutic choices.​

This precision extends beyond eczema: similar immune biomarker approaches are being used to monitor psoriasis, allergic dermatitis, and even response to immune-modulating therapies like biologics or systemic corticosteroids. As these technologies advance, clinicians will be able to distinguish between disease subtypes, track immune normalization, and reduce reliance on trial-and-error treatment.

In the context of eczema and TSW, diagnostics that can differentiate between active inflammation, barrier dysfunction, or steroid-induced immune suppression would be invaluable for tailoring care. Coupled with biomarker-guided immune support—through anti-inflammatory nutrition, microbiome modulation, or targeted biologic therapy—patients could achieve better, longer-lasting outcomes.

In Summary

Biomarker testing offers an innovative avenue for understanding immune system dysregulation at the molecular level. For those with eczema or topical steroid withdrawal, it opens the door to earlier detection, more precise diagnosis, and immune-targeted treatment strategies. Studies demonstrate that immune cytokines like IL-13, IL-8, IL-18, and TARC play central roles in eczema’s pathogenesis and could help predict disease onset or severity. Meanwhile, advanced skin mapping and non-invasive biomarker sampling represent significant steps toward truly personalized dermatologic care.

By revealing the body’s immune patterns, biomarker testing empowers clinicians and patients to not only treat symptoms but to address the root causes of immune dysfunction, creating opportunities for both skin healing and systemic immune resilience.

References

1. Gorelick J, Nguyen A, Schneider SK, Martel BC, Madsen DE, Armstrong AW. Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment. American Journal of Clinical Dermatology. 2025;26(2):199–211. doi:10.1007/s40257-024-00913-9. [PMCID: PMC11850464]​

2. Sang J, Ye X. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation. Frontiers in Immunology. 2023;14:1268331. doi:10.3389/fimmu.2023.1268331.​

3. EADV (European Academy of Dermatology and Venereology). Non-invasive skin immune biomarker test helps predict development of eczema in babies: new study finds. 2022.

4. HealthCentral. Topical Steroid Withdrawal: Why It’s Not Just Eczema. 2025.

5. National Eczema Association. Topical Steroid Withdrawal (TSW): What We Know. 2025.

6. Nature Communications. Immune modules to guide diagnosis and personalized medicine in inflammatory skin diseases. Nature Communications. 2024;12(54559). doi:10.1038/s41467-024-54559-6.

7. PubMed Central. Key regulators and biomarkers of skin barrier function in atopic dermatitis. Scientific Reports. 2025;15(46250).

8. Frontiers in Allergy. Biomarkers to aid in diagnosis of allergic contact dermatitis. Frontiers in Allergy. 2025;6:1564588.

9. ScienceDirect. Laboratory biomarkers of an effective immune response. Journal of Allergy and Immunology Research. 2021;8(3):185–200.

10. Dermatology Times. Skin immune biomarker test helps predict eczema in infants. Dermatology Times. 2022.

11. Nance K, et al. Breaking the cycle: a comprehensive exploration of topical steroid withdrawal. Journal of Clinical Dermatology and Immunotherapy. 2025;30:11994697.

12. Bioinformatics‐Based Analysis. Reveals diagnostic biomarkers and immune infiltration features in atopic dermatitis. International Journal of Molecular Sciences. 2025;12051981.